Financhill
Sell
36

MRKR Quote, Financials, Valuation and Earnings

Last price:
$3.17
Seasonality move :
27.43%
Day range:
$3.09 - $3.40
52-week range:
$2.44 - $5.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.47x
Volume:
42.4K
Avg. volume:
76.4K
1-year change:
-43.45%
Market cap:
$33.3M
Revenue:
--
EPS (TTM):
-$1.10

Analysts' Opinion

  • Consensus Rating
    Marker Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $19.00, Marker Therapeutics has an estimated upside of 510.93% from its current price of $3.11.
  • Price Target Downside
    According to analysts, the lowest downside price target is $19.00 representing 100% downside risk from its current price of $3.11.

Fair Value

  • According to the consensus of 1 analyst, Marker Therapeutics has 510.93% upside to fair value with a price target of $19.00 per share.

MRKR vs. S&P 500

  • Over the past 5 trading days, Marker Therapeutics has underperformed the S&P 500 by -6.65% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Marker Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Marker Therapeutics has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Marker Therapeutics reported revenues of --.

Earnings Growth

  • Marker Therapeutics earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Marker Therapeutics reported earnings per share of -$0.26.
Enterprise value:
24.3M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-2.83x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue -- -- -- -- --
Gross Profit -- -- -- -- --
Operating Income -$30.7M -$14.7M -$10.2M -$3.2M -$2.4M
EBITDA -$29M -$14.7M -$10.2M -$3.2M -$2.4M
Diluted EPS -$4.30 -$1.07 -$1.10 -$0.34 -$0.26
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $30.3M $51.4M $22.4M $19.5M $10.9M
Total Assets $48.6M $71.9M $41.1M $19.5M $10.9M
Current Liabilities $6M $8.2M $11.3M $2.8M $3.5M
Total Liabilities $18M $19.7M $18.5M $2.8M $3.5M
Total Equity $30.6M $52.3M $22.6M $16.7M $7.4M
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations -$25.5M -$20.4M -$8.6M -$1.1M $1.2M
Cash From Investing -$5.2M $18.5M -- -- --
Cash From Financing $63.6K $1.2M $100.5K $479.3K $1.7K
Free Cash Flow -$25.5M -$20.4M -$8.6M -$1.1M $1.2M
MRKR
Sector
Market Cap
$33.3M
$47.7M
Price % of 52-Week High
51.92%
46.05%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-43.46%
-33.33%
Beta (5-Year)
1.484
0.760
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $3.46
200-day SMA
Sell
Level $3.94
Bollinger Bands (100)
Sell
Level 2.88 - 3.94
Chaikin Money Flow
Sell
Level -76M
20-day SMA
Sell
Level $3.75
Relative Strength Index (RSI14)
Sell
Level 41.81
ADX Line
Sell
Level 35.85
Williams %R
Buy
Level -99.3007
50-day SMA
Sell
Level $3.71
MACD (12, 26)
Sell
Level -0.07
25-day Aroon Oscillator
Buy
Level 60
On Balance Volume
Neutral
Level 215.8M

Financial Scores

--
Altman Z-Score (Annual)
Level (--)
--
CA Score (Annual)
Level (--)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (9)
--
Ohlson Score
Level (--)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

Stock Forecast FAQ

In the current month, MRKR has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MRKR average analyst price target in the past 3 months is $19.00.

  • Where Will Marker Therapeutics Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Marker Therapeutics share price will rise to $19.00 per share over the next 12 months.

  • What Do Analysts Say About Marker Therapeutics?

    Analysts are divided on their view about Marker Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Marker Therapeutics is a Sell and believe this share price will drop from its current level to $19.00.

  • What Is Marker Therapeutics's Price Target?

    The price target for Marker Therapeutics over the next 1-year time period is forecast to be $19.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is MRKR A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Marker Therapeutics is a Buy. 1 of 1 analysts rates the stock a Buy at this time.

  • How Can I Buy Shares Of MRKR?

    You can purchase shares of Marker Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Marker Therapeutics shares.

  • What Is The Marker Therapeutics Share Price Today?

    Marker Therapeutics was last trading at $3.17 per share. This represents the most recent stock quote for Marker Therapeutics. Yesterday, Marker Therapeutics closed at $3.11 per share.

  • How To Buy Marker Therapeutics Stock Online?

    In order to purchase Marker Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Broadcom vs American Express: Which Is Best?
Broadcom vs American Express: Which Is Best?

Chip giant Broadcom Inc. (NASDAQ:AVGO) and card company American Express…

Why Is Adobe Stock Dropping?
Why Is Adobe Stock Dropping?

Why is Adobe stock dropping? A combination of underwhelming fiscal…

Why Is 3M Stock Going Up?
Why Is 3M Stock Going Up?

After a decade-long slump in new product introductions, the leading…

Stock Ideas

Buy
58
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 41x

Buy
51
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Sell
48
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 36x

Alerts

Buy
77
FTAI alert for Jan 2

FTAI Aviation [FTAI] is up 0.29% over the past day.

Buy
56
QMCO alert for Jan 2

Quantum [QMCO] is up 0.83% over the past day.

Buy
78
BMA alert for Jan 2

Banco Macro SA [BMA] is up 12.94% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock